Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-01-18
2011-01-18
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S205100, C424S199100, C424S186100, C424S185100, C424S209100, C424S093600, C435S005000, C435S069100, C530S350000
Reexamination Certificate
active
07871626
ABSTRACT:
The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.
REFERENCES:
patent: 6719979 (2004-04-01), Peeters et al.
patent: 6740325 (2004-05-01), Arnon et al.
Hien et al., Avian Influenza A (H5N1) in 10 patients in Vietnam, 2004, New England Journal of Medicine, vol. 350, No. 12, pp. 1179-1188.
Li et al., Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia, 2004, Nature, vol. 430, pp. 209-213.
Stephenson et al., Cross-Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59-Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine:A Potential Priming Strategy, 2005, Journal of Infectious Diseases, vol. 191, pp. 1210-1215.
Glaser et al., A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity, 2005, Journal of Virology, vol. 79, No. 17, pp. 11533-11536.
Lee et al., Generation of reassortant influenza vaccines by reverse genetics that allows utilizations of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza, 2004, Vaccine, vol. 22, pp. 3175-3181.
Hatta et al., Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses, 2001, Science, vol. 293, pp. 1840-1842.
Martin et al., Studies of the Binding Properties of Influenza Hemagglutinin Receptor-Site Mutants, 1998, Virology, vol. 241, pp. 101-111.
Both, et al., 1983. “Hemagglutinin of Swine Influenza Virus: A Single Amino Acid Change Pleiotropically Affects Viral Antigenicity nad Replication”. PNAS 80: 6996-7000.
Gambrayan, et al., 2005. “Receptor specificity of influenza viruses from birds and mammals: New data on involvement of the inner fragments of the carbohydrate chain”. Virology 334: 276-283.
Hoffman, et al., 2000. “A DNA transfection system for generation of influenza A virus from eight plasmids”. PNAS 97: 6108-6113.
Govorkova, et al., 2005. “Lethality of Ferrets of H5N1 Influenza Viruses Isolated from Humans and Poultry in 2004”. Journal of Virology 79: 2191-2198.
Hague et al., Confronting Potential Influenza A (H5N1) Pandemic with Better Vaccines, Emerging Infectious Diseases, 2007, 13 (10):1512-1518.
Hoffmann et al., Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines, Proceedings of the National Academy of Sciences USA, 2005, 102 (36):12915-12920.
Neumann and Kawaoka, Host Range Restriction and Pathogenicity in the Context of Influenza Pandemic, Emerging Infectious Diseases, 2006, 12 (6):881-886.
Takahashi et al., Protective Immunity Afforded by Inactivated H5N1 (NIBRG-14) Vaccine Requires Antibodies against Both Hemagglutinin and Neuraminidase in Mice, The Journal of Infectious Diseases, 2009, 199 (11):1629-1637.
Y. Guan, et al., “H5N1 influenza: A protean pandemic threat”, Proc. Natl. Acad. Sci. U.S.A., 2004, 101(21):8156-8161.
B. Lewin, “Genes VII”, Oxford Univ. Press, 2000, p. 778.
Govorkova Elena A.
Hoffmann Erich
Lipatov Aleksandr S.
Webby Richard J.
Webster Robert G.
Blumel Benjamin P
Fish & Richardson P.C.
Lucas Zachariah
St. Jude Children's Research Hospital
LandOfFree
Modified influenza virus for monitoring and improving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified influenza virus for monitoring and improving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified influenza virus for monitoring and improving... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2741391